AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02879552 — intervention group
Intervention type: PROCEDURE
Intervention: Brassiere suture with blepharoplasty
Description: Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues.
Study NCT04259905 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active video game teleconference support group
Description: 12 sessions of teleconferenced support group meetings, including active video game play + self-paced walking monitored by Fitbit wearable device
Study NCT04259905 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard support group + pedometer
Description: 3 monthly sessions of in-person standard support group meetings + self-paced walking monitored by pedometer
Study NCT02875340 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VAL401
Description: Risperidone formulated into a liquid lipid filled capsule
Study NCT03351894 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Femtosecond laser assisted cataract surgery
Description: Ziemer Z8 femtosecond laser assisted cataract surgery
Study NCT03351894 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Conventional phacoemulsification
Description: conventional phacoemulsification with infinity phaco
Study NCT02014402 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bovine thrombin
Description: Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
Study NCT02102217 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PRECious
Description: Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
Study NCT04013451 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acts of kindness
Description: Both intervention and control groups will receive an email with access to a relaxation and stress management booklet from Western University's (UWO) Wellness Education Centre (http://studentexperience.uwo.ca/docs/RelaxationAndStressManagement.pdf). In addition, the intervention group will be asked to (1) complete and log/submit a minimum of three deliberate acts of kindness per day for one month, and (2) join the study-dedicated online site to connect with, support, and share experiences and ideas with each other around acts of kindness.
Study NCT02672488 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Standard treatment for advanced HCC
Study NCT02672488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Standard treatment for advanced HCC
Study NCT02672488 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
Study NCT04138173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tele coaching intervention
Description: A.Education about the importance of PA. During a one-to-one interview with the coach motivation, self-efficacy, barriers, favorite activities and strategies to become more active are discussed.~B. Step counter providing direct feedback.~C.A smartphone with a project-tailored application. The application provides automated coaching by displaying an activity goal (number of steps) and feedback on a daily basis. The feedback comes with a graphical presentation. Patients' targets are automatically revised weekly.~D.Telephone contacts triggered in the case of non-compliance with wearing the step counter, failure to transmit data or failure to progress. Coaches are alerted by a note at the coaches' backend to take contact with the patient if needed.
Study NCT02204527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: supplementation of 100.000 IU of vitamin D3
Description: supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
Study NCT02204527 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo pill
Description: Placebo
Study NCT00878735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Zen meditation
Description: Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
Study NCT03991195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic supplemented intervention
Description: In this project, taking the method of random, double blindness and control, the probiotic supplemented group with aMCI will take Bifidobacterium for three months. After that, cognitive changes will be test to investigate the effectiveness of probiotic supplementation.
Study NCT03991195 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: In this project, taking the method of random, double blindness and control, the placebo group with aMCI will take placebo for three months. After that, cognitive changes will be test.
Study NCT01866436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multimedia group
Description: Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
Study NCT01866436 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study Day Group
Description: Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection
Study NCT04808609 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumme mobile phone application
Description: Lumme mobile phone app provides smoking cessation support and tracks smoking behaviors
Study NCT04808609 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Standard of Care
Description: Smoking cessation counseling and nicotine replacement therapy
Study NCT04808609 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard of Care
Description: Smoking cessation counseling and nicotine replacement therapy
Study NCT05663489 — intervention group
Intervention type: BEHAVIORAL
Intervention: Bergen 4-Day Treatment (B4DT)
Description: A concentrated and exposure-based psychological treatment over four consecutive days
Study NCT02436382 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: change in temperature
Description: increase in ambient room temperature
Study NCT01152723 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: 2 mg, Single Dose
Study NCT01152723 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: 2 mg, Single Dose
Study NCT00970086 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacain/levobupivacaine
Description: Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.~Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%.
Study NCT04027686 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser Therapy
Description: Adjunctive application of laser therapy in the periodontal pocket
Study NCT04027686 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgical Scaling and Root Planing
Description: Scaling to remove calculus deposits and root planing to smooth root surfaces
Study NCT04027686 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Non-surgical Scaling and Root Planing
Description: Scaling to remove calculus deposits and root planing to smooth root surfaces
Study NCT00727389 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physiotherapy
Description: Exercise two days a week for six month
Study NCT05044741 — intervention group
Intervention type: PROCEDURE
Intervention: Emergency surgical enterostomy
Description: Emergency surgical enterostomy
Study NCT02541721 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LabiaStick#01
Description: This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.~The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area.
Study NCT02205892 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lupeol
Description: Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
Study NCT02205892 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo vehicle
Description: Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
Study NCT00226434 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Early antiretroviral treatment
Description: The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
Study NCT00226434 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Late antiretroviral treatment
Description: The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
Study NCT00113516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: AUC of 6 mg\*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
Study NCT03918980 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LOU064
Description: LOU064 will be administered as oral capsules in parts 1 to 6.
Study NCT00113516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: 175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
Study NCT00113516 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sunitinib
Description: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
Study NCT01782196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced one piece drainable pouch with Type A mouldable adhesive
Study NCT01782196 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Enhanced one piece drainable pouch with Type B mouldable adhesive
Study NCT01646671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: LCZ696 200 mg tablet once daily
Study NCT01646671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
Study NCT01646671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LCZ696
Description: 2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
Study NCT02074735 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive ingredient matching the active comparator in appearance
Study NCT02074735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Citicoline
Description: Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
Study NCT00559897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3'-deoxy-3'-[18F]FLT
Description: Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
Study NCT00559897 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography
Description: Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
Study NCT03705039 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pulsed Ultrasound Treatment
Description: Patients will receive treatment with 1 MHz probe with the intensity of 1w/cm2, pulsed at a ratio of 1:4 for 10 minutes and at an interval of 3 sessions per week during 8 weeks, a total of 24 sessions.
Study NCT03705039 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: Sham US will be applied to control group for the same times and periods as treatment group. A home exercise program will be given to both of two groups which contains knee range of motion and isometric strengthening exercises.
Study NCT03223103 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Poly-ICLC
Description: Poly-ICLC 100mcg per peptide per dose
Study NCT03223103 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tumor Treating Fields
Description: an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
Study NCT03223103 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peptides
Description: synthetic long peptides (SLP) as vaccine substrate
Study NCT00578773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidex otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT00578773 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin otic solution
Description: 4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
Study NCT00578773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT00578773 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT00578773 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Tympanostomy tubes
Description: Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
Study NCT01646034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin, thiotepa, and cyclophosphamide
Description: tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
Study NCT01646034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)
Description: * chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide~* chemotherapy naïve;1 cycle of dose-dense Adriamycin and cyclophosphamide followed by 4 cycles of carboplatin and paclitaxel~* previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel~* previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine
Study NCT03755765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Study NCT03755765 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Study NCT03755765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BB-12
Description: Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
Study NCT03755765 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Yogurt without Bifidobacterium animalis subsp. lactis BB-12 (BB-12)
Study NCT04536844 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mobile application MyDignio (follow disease activity by assigning questionnaires to participants)
Description: An electronic application available both on Apple store and Android play which the patients can download for free will be used to collect data from the Telehealth follow up group. This group will be compared to conventional outpatient clinic follow-up group.
Study NCT04536844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Conventional prescheduled follow-up
Description: Patients will be followed in the outpatient clinic by prescheduled follow-up
Study NCT00652457 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: 10 mg BID x 3 months
Study NCT00652457 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Memantine
Description: 10 mg BID x 3 months
Study NCT03636490 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological Stress Intervention
Description: Participant will be shown a series of words for five minutes and a research coordinator will ask him/her to name the color of each (Stroop Color-Word Conflict Task). Then, for another five minutes, the participant will be asked to count backwards out loud by sevens starting from 1,000 (Mental Arithmetic Task). The research assistant will ask the participant to work as quickly and accurately as possible for both tasks.
Study NCT04097379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LRX712
Description: LRX712 intra-articular injections
Study NCT04097379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intra-articular injections
Study NCT03698682 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500mg
Description: One tablet per day for 7 days.
Study NCT03898817 — intervention group
Intervention type: OTHER
Intervention: taking of cutaneous cells
Description: Taking of cutaneous cells by biopsy Sample of blood
Study NCT03139656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Values Clarification
Description: This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, \& Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
Study NCT03139656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Planning
Description: Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer \& Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit.
Study NCT03139656 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Combined
Description: Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When \[I encounter the specified obstacle\], I will do \[X\] and remember \[values-based statement or image identified during values clarification exercise\]. They will be asked to rehearse these if-then statements to themselves before the end of the visit.
Study NCT04360824 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Intermediate dose thromboprophylaxis
Description: 2) Patients randomized to the intervention arm will receive intermediate-dose enoxaparin (1 mg/kg Subcutaneously daily if BMI\<30kg/m2 or 0.5 mg/kg Subcutaneously twice daily if BMI ≥ 30kg/m2).
Study NCT04360824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care thromboprophylaxis
Description: Patients randomized to the standard of care arm will receive standard prophylactic dose enoxaparin (40 mg subcutaneously daily if BMI \<30kg/m2 and 30 mg subcutaneously twice daily or 40 mg subcutaneously twice daily if BMI ≥ 30 kg/m2).
Study NCT00968110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omalizumab
Description: Dosing table established for omalizumab
Study NCT02772068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Istaroxime
Description: Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.